Recce Pharmaceuticals (OTCPK:RECE.F) - Prezzo delle azioni, notizie e analisi

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

RECE.F Panoramica delle azioni

Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic anti–infectives in Australia, the United Kingdom, and the United States.

Informazioni sull'azienda

RECE.F analisi fondamentale
Punteggio fiocco di neve
Valutazione	1/6
Crescita futura	0/6
Prestazioni passate	0/6
Salute finanziaria	6/6
Dividendi	0/6

Premi

Analisi del rischio

Le azioni sono altamente illiquide

Si prevede che gli utili diminuiranno in media di 56.3% all'anno per i prossimi 3 anni

Attualmente non redditizio e non si prevede che diventerà redditizio nei prossimi 3 anni

Gli azionisti sono stati diluiti nell'ultimo anno

+ 2 più rischi

Recce Pharmaceuticals Ltd Concorrenti

Aclaris Therapeutics

NasdaqGS:ACRS

US$84.9m

SCYNEXIS

NasdaqGM:SCYX

US$54.5m

Ocuphire Pharma

NasdaqCM:OCUP

US$34.6m

Nutriband

NasdaqCM:NTRB

US$66.6m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Recce Pharmaceuticals
Prezzi storici delle azioni
Prezzo attuale dell'azione	AU$0.60
Massimo di 52 settimane	AU$0.60
Minimo di 52 settimane	AU$0.55
Beta	1.13
1Variazione di 1 mese	0%
Variazione a 3 mesi	9.09%
Variazione di 1 anno	n/a
3Variazione a 3 anni	n/a
Variazione a 5 anni	n/a
Variazione dall'IPO	0%

Notizie e aggiornamenti recenti

Recent updates

Rendimenti per gli azionisti

	RECE.F	US Pharmaceuticals	US Mercato
7D	0%	-0.4%	0.1%
1Y	n/a	18.5%	32.2%

Ritorno vs Industria: Dati insufficienti per determinare come si è comportato RECE.F rispetto al settore US Pharmaceuticals.

Rendimento vs Mercato: Dati insufficienti per determinare la performance di RECE.F rispetto al mercato US.

Volatilità dei prezzi

Is RECE.F's price volatile compared to industry and market?
RECE.F volatility
RECE.F Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	9.5%
Market Average Movement	6.4%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	3.1%

Prezzo delle azioni stabile: RECE.F non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: Dati insufficienti per determinare la variazione della volatilità di RECE.F nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2007	n/a	James Graham	www.recce.com.au

Recce Pharmaceuticals Ltd Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Recce Pharmaceuticals con la sua capitalizzazione di mercato?
RECE.F statistiche fondamentali
Capitalizzazione di mercato	US$67.24m
Guadagni(TTM)	-US$7.38m
Ricavi(TTM)	US$4.40m

15.3x

Rapporto P/S

-9.1x

Rapporto P/E

RECE.F è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
RECE.F Conto economico (TTM)
Ricavi	AU$6.75m
Costo del fatturato	AU$8.01m
Profitto lordo	-AU$1.26m
Altre spese	AU$10.05m
Guadagni	-AU$11.32m

Ultimi guadagni dichiarati

Dec 31, 2023

Prossima data di guadagno

n/a

Utile per azione (EPS)	-0.051
Margine lordo	-18.73%
Margine di profitto netto	-167.74%
Rapporto debito/patrimonio netto	418.1%

Come si è comportato RECE.F nel lungo periodo?

Vedi performance storica e confronto

RECE.F Panoramica delle azioni

Premi

Analisi del rischio

Recce Pharmaceuticals Ltd Concorrenti

NasdaqGS:ACRS

US$84.9m

NasdaqGM:SCYX

US$54.5m

NasdaqCM:OCUP

US$34.6m

NasdaqCM:NTRB

US$66.6m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Recce Pharmaceuticals Ltd, Annual General Meeting, Nov 06, 2024

Recce Pharmaceuticals Announces Positive Preclinical Efficacy Data Against WHO Priority Pathogen Acinetobacter Baumannii

Recce Pharmaceuticals Ltd has filed a Follow-on Equity Offering in the amount of AUD 2 million.

Recce Pharmaceuticals Reports Positive Data from Phase I/Ii Urinary Tract Infection (Uti) / Urosepsis Rapid Infusion Trial of Recce® 327

Recce Pharmaceuticals Ltd. Receives Ethics Approval to Broaden RECCE 327 Gel Trials Across All Topical Bacterial Skin Infections

Recce Pharmaceuticals Announces Addition of RECCE® 327 to the World Health Organization’S List of Antibacterial Products in Clinical Development

Recent updates

Recce Pharmaceuticals Ltd, Annual General Meeting, Nov 06, 2024

Recce Pharmaceuticals Announces Positive Preclinical Efficacy Data Against WHO Priority Pathogen Acinetobacter Baumannii

Recce Pharmaceuticals Ltd has filed a Follow-on Equity Offering in the amount of AUD 2 million.

Recce Pharmaceuticals Reports Positive Data from Phase I/Ii Urinary Tract Infection (Uti) / Urosepsis Rapid Infusion Trial of Recce® 327

Recce Pharmaceuticals Ltd. Receives Ethics Approval to Broaden RECCE 327 Gel Trials Across All Topical Bacterial Skin Infections

Recce Pharmaceuticals Announces Addition of RECCE® 327 to the World Health Organization’S List of Antibacterial Products in Clinical Development

Recce Pharmaceuticals Ltd Doses First Participants in Next Cohort of Phase I/II Urinary Tract Infections and Urosepsis Rapid Infusion Clinical Trial

Recce Pharmaceuticals Reports Positive Preclinical Data of Recce® 327 in Lung Infection Pilot Study

Recce Pharmaceuticals Ltd Receives New Patent in China for RECCE Anti-Infectives from China National Intellectual Property Administration

Recce Pharmaceuticals Ltd. Announces Safety Committee Approves High Dose of 4,000mg in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis

Recce Pharmaceuticals Ltd. Completes 5,000 RECCE 327 Doses Week Under Good Manufacturing Practice

Recce Pharmaceuticals Ltd Receives New Patent in Israel for Recce Anti-Infectives

Recce Pharmaceuticals Completes Dosing Cohort in Phase I/II Trial of Recce® 327 for Urinary Tract Infections and Urosepsis

Recce Pharmaceuticals Ltd Doses Next Cohort in Phase I/II Trial of RECCE 327 for Urinary Tract Infections and Urosepsis

Recce Pharmaceuticals Reports Positive Phase I/II Trial Results of RECCE 327 for the Treatment of Diabetic Foot Infections

Recce Pharmaceuticals Receives Ausindustry Advanced Overseas Finding for Synthetic Anti-Infective Research & Development Program

Recce Pharmaceuticals Ltd Reports Positive Preclinical Data of RECCE 327 Against Gonorrhoeae

Recce Pharmaceuticals Limited Announces Canadian Patent Granted for Recce® Anti-Infectives

Recce Pharmaceuticals Ltd Completes Dosing First Subjects at 15-Minute Infusion Rate in a Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis

Recce Pharmaceuticals Ltd Announces Safety Committee Approves Faster Infusion Rate in Phase I/Ii Trial of Recce® 327 for Urinary Tract Infections and Urosepsis

Recce Pharmaceuticals Ltd has completed a Follow-on Equity Offering in the amount of AUD 3.022261 million.

Recce Pharmaceuticals Ltd has completed a Follow-on Equity Offering in the amount of AUD 3.022261 million.

Recce Pharmaceuticals Ltd has completed a Follow-on Equity Offering in the amount of AUD 2.715261 million.

Recce Pharmaceuticals Completes Dosing in Phase I/II Clinical Trial of Recce® 327 for Urinary Tract Infections

Recce Pharmaceuticals Ltd, Annual General Meeting, Nov 08, 2023

Recce Pharmaceuticals Ltd Provides Additional Positive Update on Patients Treated Under "Special Access Scheme"

Recce Pharmaceuticals Ltd Announces Safety Committee Approves Next Dose of Recce®? 327 At 3,000Mg in Phase I/Iiuti/Urosepsis Rapid Infusion Clinical Trial

Recce Pharmaceuticals Ltd Doses Patients in Phase I/II Clinical Trial of Recce 327 for Diabetic Foot Infections

Recce Pharmaceuticals Ltd. Completes Stage 1 Data Analysis of Phase I/II Clinical Trial for the Treatment of Burn Wound Infections

Recce Pharmaceuticals Ltd Provides Positive Update on Patients Treated with RECCE®? 327 Under "Special Access Scheme"

Recce Pharmaceuticals Completes First Cohort Dosing of Phase l/ll UTI Rapid Infusion Clinical Trial at Scientia Clinical Research

Recce Pharmaceuticals Achieves Positive Phase I Clinical Trial Data of RECCE(R) 327 as an Intravenous Infusion Formulation

Recce Pharmaceuticals Limited Announces First Cohort Dosed in Recce®? 327 Rapid Infusion Phase I/II Urinary Tract Infection (UTI) Clinical Trial

Recce Pharmaceuticals to Be Granted Anti-Viral Patent in Australia for RECCE® Anti-Infectives

Recce Pharmaceuticals Limited Announces Australian Patent Office Issued Notification of Intent to Grant Recce's Patent Family 3

Recce Pharmaceuticals Ltd Receives Ethics Approval to Start Phase 1/2 Study Evaluating RECCE(R) 327 in Patients with Diabetic Foot Infections

Recce Pharmaceuticals Ltd Receives Ethics Approval to Start Phase I/II Diabetic Foot Ulcer Study

Recce Pharmaceuticals Ltd Provides RECCE 327 SARS-CoV-2 Study Update

Recce Pharmaceuticals Ltd Provides RECCE 327 SARS-CoV-2 Study Update

Recce Pharmaceuticals Announces Expansion and Acceleration of Clinical Programs

Recce Pharmaceuticals Ltd, Annual General Meeting, Nov 14, 2022

Recce Pharmaceuticals Appoints Alistair McKeough to Its Board of Directors and Maggie Niewidok as Company Secretary

Recce Announces Management Changes

Recce Pharmaceuticals Ltd Reports Positive Safety Data from Seventh Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327

Rendimenti per gli azionisti

Volatilità dei prezzi

Informazioni sull'azienda

Recce Pharmaceuticals Ltd Riepilogo dei fondamenti

15.3x

-9.1x

Guadagni e ricavi